162 related articles for article (PubMed ID: 37468447)
21. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
Reungwetwattana T; Liang Y; Zhu V; Ou SI
Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
[TBL] [Abstract][Full Text] [Related]
22. MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.
Drilon A
Clin Cancer Res; 2016 Jun; 22(12):2832-4. PubMed ID: 27009743
[TBL] [Abstract][Full Text] [Related]
23. Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas.
Fujino T; Suda K; Sakai K; Murakami I; Shimizu S; Ohara S; Koga T; Hamada A; Soh J; Nishio K; Mitsudomi T
Clin Lung Cancer; 2022 May; 23(3):e185-e195. PubMed ID: 34702670
[TBL] [Abstract][Full Text] [Related]
24. [MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].
Baldacci S; Kherrouche Z; Descarpentries C; Wislez M; Dansin E; Furlan A; Tulasne D; Cortot AB
Rev Mal Respir; 2018 Oct; 35(8):796-812. PubMed ID: 30174236
[TBL] [Abstract][Full Text] [Related]
25. c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination.
Taher TE; Tjin EP; Beuling EA; Borst J; Spaargaren M; Pals ST
J Immunol; 2002 Oct; 169(7):3793-800. PubMed ID: 12244174
[TBL] [Abstract][Full Text] [Related]
26. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
Lee GD; Lee SE; Oh DY; Yu DB; Jeong HM; Kim J; Hong S; Jung HS; Oh E; Song JY; Lee MS; Kim M; Jung K; Kim J; Shin YK; Choi YL; Kim HR
J Thorac Oncol; 2017 Aug; 12(8):1233-1246. PubMed ID: 28502721
[TBL] [Abstract][Full Text] [Related]
27. Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation.
Tanaka H; Taima K; Makiguchi T; Nakagawa J; Niioka T; Tasaka S
Cancer Commun (Lond); 2021 Jan; 41(1):83-87. PubMed ID: 33387444
[TBL] [Abstract][Full Text] [Related]
28. Distinct MET Protein Localization Associated With MET Exon 14 Mutation Types in Patients With Non-small-cell Lung Cancer.
Qiu T; Li W; Zhang T; Xing P; Huang W; Wang B; Chu L; Guo L; Liu X; Li Y; Ying J; Li J
Clin Lung Cancer; 2018 Jul; 19(4):e391-e398. PubMed ID: 29338938
[TBL] [Abstract][Full Text] [Related]
29. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
Salgia R; Sattler M; Scheele J; Stroh C; Felip E
Cancer Treat Rev; 2020 Jul; 87():102022. PubMed ID: 32334240
[TBL] [Abstract][Full Text] [Related]
30. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
31. Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.
Shalata W; Yakobson A; Weissmann S; Oscar E; Iraqi M; Kian W; Peled N; Agbarya A
Oncology; 2022; 100(9):467-474. PubMed ID: 35679833
[No Abstract] [Full Text] [Related]
32. Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non-small cell lung cancer: A case report.
Ikeo S; Yasuda N; Sakai Y; Hayashi Y; Sokai A; Iwata T; Nishimura T
Thorac Cancer; 2023 Apr; 14(10):958-960. PubMed ID: 36810936
[TBL] [Abstract][Full Text] [Related]
33. A lung adenocarcinoma patient harboring MET c. 3028 + 2 T >A variant sensitive to crizotinib treatment.
Jiang R; Wei D; Tan Y; Duan Q
Invest New Drugs; 2022 Aug; 40(4):870-873. PubMed ID: 35551560
[TBL] [Abstract][Full Text] [Related]
34. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
Tan YH; Krishnaswamy S; Nandi S; Kanteti R; Vora S; Onel K; Hasina R; Lo FY; El-Hashani E; Cervantes G; Robinson M; Hsu HS; Kales SC; Lipkowitz S; Karrison T; Sattler M; Vokes EE; Wang YC; Salgia R
PLoS One; 2010 Jan; 5(1):e8972. PubMed ID: 20126411
[TBL] [Abstract][Full Text] [Related]
35. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
36. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
37. MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population.
Lung J; Hung MS; Lin YC; Lee KF; Jiang YY; Huang SL; Fang YH; Lu MS; Lin CK; Yang TM; Lin PY; Hsieh MJ; Tsai YH
PLoS One; 2019; 14(8):e0220670. PubMed ID: 31369639
[TBL] [Abstract][Full Text] [Related]
38. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
Qin RY; Liu LS; Zhang HY; Lu CH; Guo XY; Zhang LY; Yuan XB; Xue HH
Medicine (Baltimore); 2021 Jan; 100(4):e24300. PubMed ID: 33530219
[TBL] [Abstract][Full Text] [Related]
39. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.
Peschard P; Fournier TM; Lamorte L; Naujokas MA; Band H; Langdon WY; Park M
Mol Cell; 2001 Nov; 8(5):995-1004. PubMed ID: 11741535
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
